Edition:
United States

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

3.50USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.57%)
Prev Close
$3.52
Open
$3.50
Day's High
$3.59
Day's Low
$3.47
Volume
1,037
Avg. Vol
8,298
52-wk High
$5.25
52-wk Low
$2.37

Latest Key Developments (Source: Significant Developments)

AzurRx Biopharma files for mixed shelf offering of up to $10 mln
Wednesday, 1 Nov 2017 05:52pm EDT 

Nov 1 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​.  Full Article

Azurrx Biopharma, Mayoly Spindler announce IMPD submission
Friday, 20 Oct 2017 08:30am EDT 

Oct 20 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission.Azurrx Biopharma - ‍IMPD submitted via European Medicines Agency clinical trial portal for approval prior to opening of clinical centers in France.  Full Article

AzurRx BioPharma files for stock shelf of upto $10 mln
Wednesday, 11 Oct 2017 06:08pm EDT 

Oct 11 (Reuters) - Azurrx Biopharma Inc :Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing‍​‍​.  Full Article

AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency
Wednesday, 27 Sep 2017 08:30am EDT 

Sept 27 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi).AzurRx Biopharma Inc - ‍no serious adverse events or notable mild to moderate events have been reported in open-label, ascending dose phase IIA trial​.AzurRx Biopharma Inc - ‍favorable trends were also observed on other evaluated endpoints​.AzurRx Biopharma Inc - ‍secondary efficacy endpoints are consistently aligning with CFA data and safety profile of MS1819-SD remains favorable​.  Full Article

Azurrx reaches 6th patient enrollment of midstage trial for pancreas drug
Wednesday, 23 Aug 2017 08:00am EDT 

Aug 23 (Reuters) - Azurrx Biopharma Inc :Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis.Azurrx Biopharma Inc- ‍results on first six patients expected in September from phase IIA trial of MS1819​.Azurrx Biopharma Inc- added additional clinical trial site to further support enrollment in study and other planned future studies.  Full Article

Azurrx Biopharma enters into sublicense agreement with Transchem
Friday, 11 Aug 2017 08:50pm EDT 

Aug 11 (Reuters) - Azurrx Biopharma Inc -:Azurrx Biopharma Inc - ‍on August 7, 2017, Azurrx Biopharma, Inc entered into a sublicense agreement with Transchem, Inc. - sec filing​.Azurrx Biopharma- ‍transchem granted co exclusive license to patents,patent apps related to helicobacter pylori 5'-methylthioadenosine nucleosidase inhibitors​.  Full Article

Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock
Friday, 21 Jul 2017 06:32am EDT 

July 21 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock by the selling stockholders .  Full Article

Azurrx Biopharma on April 11 entered securities purchase agreement with Lincoln Park Capital Fund
Wednesday, 12 Apr 2017 09:25am EDT 

Azurrx Biopharma Inc : Azurrx Biopharma Inc- on April 11 entered securities purchase agreement with Lincoln Park Capital Fund, LLC - sec filing .Azurrx Biopharma- pursuant to agreement, issued to lpc 12% senior secured original issue discount convertible debenture in principal amount of $1.0 million.  Full Article

AzurRx BioPharma, Mayoly-Spindler initiate phase II clinical trial of MS1819-SD
Thursday, 17 Nov 2016 07:45am EST 

AzurRx BioPharma Inc : Azurrx biopharma-mayoly spindler grants co marketing rights for recombinant lipase in various geographies, including exclusive rights for north america . Azurrx biopharma inc - initial study results from ms1819-sd phase ii study are expected in first half of 2017 . Azurrx biopharma inc - azurrx and laboratoires mayoly spindler are party to a joint research and development agreement .Azurrx biopharma and mayoly-spindler announce initiation of phase ii clinical trial of ms1819-sd for exocrine pancreatic insufficiency in chronic pancreatitis patients.  Full Article

Azurrx Biopharma reports pricing of IPO
Wednesday, 12 Oct 2016 08:00am EDT 

Azurrx Biopharma Inc :Says initial public offering of 960,000 common shares priced at $5.50 per share.  Full Article

AzurRx BioPharma Inc News

BRIEF-Azurrx Biopharma Enrolls New Patients For Phase IIA Study Of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES ENROLLMENT OF THREE NEW PATIENTS FOR ITS PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:

» More AZRX.OQ News

Earnings vs. Estimates

» More Financials